Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 34 of 37 for:    Acerta Pharma

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (PROXY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04125290
Recruitment Status : Recruiting
First Posted : October 14, 2019
Last Update Posted : January 31, 2020
Iqvia Pty Ltd
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 1, 2023
Estimated Study Completion Date : September 1, 2023